Gerontology Center, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Rev Invest Clin. 2022;74(5):276-268. doi: 10.24875/RIC.22000151.
While sarcopenia is an important clinical finding in individuals diagnosed with chronic heart failure (CHF), efforts to identify a reliable biomarker capable of predicting the overall muscular and functional decline in CHF patients have been unsuccessful to date.
The objectives of this study were to study the diagnostic utility of MicroRNA (miRNA)-1-3p as a predictor of sarcopenia status in individuals diagnosed with CHF.
In total, 80 individuals with heart failure exhibiting a left ventricular ejection fraction < 50% were enrolled in this study. All patients were analyzed to assess miR-1-3p expression levels, with body composition being evaluated through dual-energy X-ray absorptiometry and sarcopenia being defined based on the sum of appendicular lean muscle mass (ALM) divided by height in meters squared and handgrip strength (HGS). In addition, the activation of the Akt/mTOR signaling pathway was evaluated in these individuals.
In total, 40 of the enrolled patients (50%) exhibited sarcopenia. Sarcopenic patients presented with increased miR-1-3p expression levels as compared to non-sarcopenic individuals (1.69 ± 0.132 vs. 1.22 ± 0.106; p < 0.05). With respect to sarcopenic indices, appendicular skeletal mass index was most strongly correlated with miR-1-3p expression, which was also strongly correlated with HGS. High levels of Akt/mTOR signaling pathway components were expressed in sarcopenic individuals, highlighting a significant relationship between miR-1-3p activity and signaling through this pathway. Moreover, miR-1-3p was identified as a specific marker for sarcopenia in individuals with CHF.
These results suggest that circulating miR-1-3p levels are related to Akt/mTOR pathway activation and can offer valuable insight into the overall physical capacity and muscular integrity of CHF patients as a predictor of sarcopenia. (Rev Invest Clin. 2022;74(5):276-83).
虽然在诊断为慢性心力衰竭（CHF）的个体中，肌肉减少症是一个重要的临床发现，但迄今为止，人们一直未能找到一种可靠的生物标志物来预测 CHF 患者的整体肌肉和功能下降。
本研究的目的是研究 MicroRNA（miRNA）-1-3p 作为预测 CHF 个体肌肉减少症状态的指标的诊断效用。
本研究共纳入 80 例左心室射血分数<50%的心力衰竭患者。所有患者均进行了 miR-1-3p 表达水平分析，通过双能 X 线吸收法评估身体成分，并根据四肢瘦体重（ALM）除以身高的平方和握力（HGS）之和定义肌肉减少症。此外，还评估了这些个体中 Akt/mTOR 信号通路的激活情况。
共纳入的 40 例患者（50%）存在肌肉减少症。与非肌肉减少症患者相比，肌肉减少症患者的 miR-1-3p 表达水平升高（1.69±0.132 比 1.22±0.106；p<0.05）。就肌肉减少症指数而言，四肢骨骼质量指数与 miR-1-3p 表达最相关，而 miR-1-3p 表达与 HGS 也有很强的相关性。肌肉减少症患者中 Akt/mTOR 信号通路成分表达水平较高，表明 miR-1-3p 活性与该通路信号之间存在显著关系。此外，miR-1-3p 被确定为 CHF 患者肌肉减少症的特异性标志物。
这些结果表明，循环 miR-1-3p 水平与 Akt/mTOR 通路激活有关，可作为肌肉减少症的预测指标，为 CHF 患者的整体身体能力和肌肉完整性提供有价值的信息。（Rev Invest Clin. 2022;74(5):276-83）。
